Edition:
United States

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

66.50USD
21 Sep 2018
Change (% chg)

$-1.00 (-1.48%)
Prev Close
$67.50
Open
$67.94
Day's High
$67.94
Day's Low
$66.01
Volume
107,501
Avg. Vol
36,267
52-wk High
$76.98
52-wk Low
$27.74

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Announces Orphan Drug Designation Granted For Transcon PTH As Treatment For Hypoparathyroidism
Wednesday, 6 Jun 2018 05:35pm EDT 

June 6 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED FOR TRANSCON PTH AS TREATMENT FOR HYPOPARATHYROIDISM.ASCENDIS PHARMA - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO TRANSCON PTH, A LONG-ACTING PRODRUG OF PARATHYROID HORMONE.ASCENDIS PHARMA A/S - PLANS TO INITIATE A PHASE 3 PROGRAM FOR TRANSCON PTH IN Q1 OF 2019.  Full Article

Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP
Tuesday, 8 May 2018 07:00am EDT 

May 8 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP.ASCENDIS PHARMA A/S - ANTICIPATES TOP-LINE DATA FROM PHASE 1 TRIAL TO BE AVAILABLE IN Q4 OF 2018.  Full Article

Ascendis Pharma Reports Full Year 2017 Financial Results
Wednesday, 28 Mar 2018 04:01pm EDT 

March 28 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS.ASCENDIS PHARMA A/S - RARE DISEASE ENDOCRINOLOGY PIPELINE ADVANCES, WITH SIGNIFICANT MILESTONES ANTICIPATED OVER NEXT TWELVE MONTHS.ASCENDIS PHARMA A/S - AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF EUR 195.4 MILLION COMPARED TO EUR 180.3 MILLION AS OF DEC 31, 2016.  Full Article

Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS
Tuesday, 20 Feb 2018 04:01pm EST 

Feb 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.ASCENDIS PHARMA A/S - COMMENCED OFFERING OF $150 MILLION ADSS.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Wednesday, 20 Dec 2017 06:31pm EST 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Thursday, 16 Nov 2017 04:01pm EST 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth
Tuesday, 26 Sep 2017 08:00am EDT 

Sept 26 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth.Ascendis Pharma A/S says ‍phase 1 trial evaluates single ascending doses and ten multiple daily doses of transcon pth​.  Full Article

Ascendis Pharma Q2 loss per share EUR 0.94
Friday, 18 Aug 2017 07:00am EDT 

Aug 18 (Reuters) - Ascendis Pharma A/S :Ascendis Pharma A/S reports second quarter 2017 financial results.Q2 loss per share EUR 0.94.Q2 earnings per share view EUR -0.73 -- Thomson Reuters I/B/E/S.Ascendis Pharma A/S - qtrly revenue EUR 444,000 versus EUR 1.1 million.  Full Article

Ascendis Pharma says initiated regulatory submissions in Australia for entry into human clinical study with transcon parathyroid hormone
Monday, 26 Jun 2017 04:08pm EDT 

June 26 (Reuters) - Ascendis Pharma A/S :Ascendis Pharma - initiated regulatory submissions in australia to enable co's entry into its first human clinical study with transcon parathyroid hormone.  Full Article

Ascendis Pharma A/S Q1 loss per share eur 0.78
Tuesday, 23 May 2017 04:01pm EDT 

May 23 (Reuters) - Ascendis Pharma A/S :Ascendis pharma a/s reports first quarter 2017 financial results.Q1 loss per share eur 0.78.Ascendis pharma a/s qtrly revenue eur 372,000 versus eur 1.26 million.Ascendis pharma a/s - as of march 31, 2017, company had cash and cash equivalents of eur 157.6 million compared to eur 180.3 million as of december 31, 2016.  Full Article

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP